TRENTON, N.J. (Legal Newsline) - Lawyers are alleging the presence of NDMA in a diabetes medication produced by Amneal Pharmaceuticals.
Amneal Pharmaceuticals is facing a class-action lawsuit filed by Michael Hann on behalf of himself and others similarly situated. The lawsuit, filed in the United States District Court for the District of New Jersey on Dec. 5, alleges that Amneal's generic medication metformin contains dangerously high levels of N-nitrosodimethylamine (NDMA), a carcinogenic and liver-damaging impurity.
Metformin is used to control high blood sugar in patients with type 2 diabetes. The complaint alleges that Amneal's manufacturing process has caused metformin to contain dangerously high levels of NDMA.
The suit further claims that despite an online pharmacy detecting high levels of NDMA in specific batches of metformin manufactured by Amneal, the company did not issue a recall and continued to claim its commitment to producing quality medicines.
Lawyers at several firms filed the case. Those firms are Carella Byrne of New Jersey; Bursor & Fisher of New York; Honik LLC of Philadelphia; and Rivero Mestre of Miami.